Search

Your search keyword '"Scrobohaci, Marie-Lorraine"' showing total 17 results
Start Over Author "Scrobohaci, Marie-Lorraine"
17 results on '"Scrobohaci, Marie-Lorraine"'

1. Traitement curatif de la maladie thromboembolique veineuse et prise en charge des thromboses veineuses sur cathéter chez les patients atteints de cancer: Méthode SOR

Author

Elias, Antoine, Debourdeau, Philippe, Renaudin, Jean Marc, Desmurs-Clavel, Hélène, Mahé, Isabelle, Elalamy, Ismail, Pavic, Michel, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desruennes, Eric, Douard, Marie-Cécile, Grange, Claire, Hocini, Hamid, Kriegel, Irène, Le Gal, Grégoire, Meyer, Guy, Mismetti, Patrick, Quéré, Isabelle, Scrobohaci, Marie-Lorraine, Lévesque, Hervé, and Farge-Bancel, Dominique

Published
2009
Full Text
View/download PDF

2. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement

Author

Coppo, Paul, Bengoufa, Djaouida, Veyradier, Agnes, Wolf, Martine, Bussel, Annette, Millot, Gael Armel, Malot, Sandrine, Heshmati, Farhad, Mira, Jean-Paul, Boulanger, Emmanuelle, Galicier, Lionel, Durey-Dragon, Marie-Agnes, Fremeaux-Bacchi, Veronique, Ramakers, Michel, Pruna, Andre, Bordessoule, Dominique, Gouilleux, Valerie, Scrobohaci, Marie-Lorraine, Vernant, Jean-Paul, Moreau, Delphine, Azoulay, Elie, Schlemmer, Benoit, Guillevin, Loic, and Lassoued, Kaiss

Subjects
HIV patients -- Medical examination, HIV patients -- Care and treatment, Von Willebrand factor -- Influence, Von Willebrand factor -- Research, Immunodeficiency -- Risk factors, Immunodeficiency -- Research, Thrombocytopenic purpura -- Risk factors, Thrombocytopenic purpura -- Care and treatment, Thrombocytopenic purpura -- Research
Published
2004

4. [Recommendations for venous thromboembolic events treatment and central venous catheter thrombosis management in cancer patients]

Author

Elias, Antoine, Debourdeau, Philippe, Renaudin, Jean Marc, Desmurs-Clavel, Hélène, Mahé, Isabelle, Elalamy, Ismail, Pavic, Michel, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desruennes, Eric, Douard, Marie-Cécile, Grange, Claire, Hocini, Hamid, Kriegel, Irène, Le Gal, Grégoire, Meyer, Guy, Mismetti, Patrick, Quéré, Isabelle, Scrobohaci, Marie-Lorraine, Lévesque, Hervé, Farge-Bancel, Dominique, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Service de Médecine Interne, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Ecole Vétérinaire de Toulouse, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Lariboisière, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Institut de Physique du Globe de Paris ( IPGP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -IPG PARIS-Université Paris Diderot - Paris 7 ( UPD7 ) -Université de la Réunion ( UR ) -Centre National de la Recherche Scientifique ( CNRS ), Génomique, développement et pouvoir pathogène ( GD2P ), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique ( INRA ), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce ( SCDCAP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche Roland Mousnier Histoire et Civilisation ( CRM ), École pratique des hautes études ( EPHE ) -Université Paris-Sorbonne ( UP4 ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Groupe de recherche sur la thrombose ( GRT (EA 3065) ), Université Jean Monnet [Saint-Étienne] ( UJM ), CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), and Normandie Université ( NU ) -Normandie Université ( NU )

Subjects
Catheterization, Central Venous, MESH : Venous Thromboembolism, MESH: Clinical Trials as Topic, MESH: Societies, Medical, MESH: Academies and Institutes, MESH : Treatment Outcome, MESH : Randomized Controlled Trials as Topic, Catheterization, MESH: Venous Thromboembolism, Central Venous, Neoplasms, Medical, MESH : Societies, Medical, Humans, MESH: Neoplasms, MESH: Thrombosis, MESH : France, Societies, Medical, Randomized Controlled Trials as Topic, MESH: Treatment Outcome, Clinical Trials as Topic, MESH: Catheterization, Central Venous, MESH: Humans, MESH : Humans, Academies and Institutes, [ SDV.SP.PHARMA ] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Thrombosis, Venous Thromboembolism, MESH : Neoplasms, MESH : Thrombosis, MESH : Clinical Trials as Topic, MESH: France, Treatment Outcome, MESH: Randomized Controlled Trials as Topic, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, France, MESH : Academies and Institutes, Societies, MESH : Catheterization, Central Venous
Abstract

International audience; The "Standards, Options: Recommendations" (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) and is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events (VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies (<< Société nationale française de médecine interne >> : SNFMI, << Société française de médecine vasculaire >> : SFMV and << Société française d'anesthésie-réanimation >> : SFAR).

Published
2009
Full Text
View/download PDF

5. [2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients]

Author

Renseigné, Non, Mahé, Isabelle, Elalamy, Ismail, Farge-Bancel, Dominique, Mismetti, Patrick, Scrobohaci, Marie-Lorraine, Hocini, Hamid, Meyer, Guy, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desmurs-Clavel, Hélène, Desruennes, Eric, Douard, Marie-Cécile, Elias, Antoine, Grange, Claire, Kriegel, Irène, Le Gal, Grégoire, Lévesque, Hervé, Pavic, Michel, Renaudin, Jean Marc, Quéré, Isabelle, Debourdeau, Philippe, Service de Médecine Interne, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Ecole Vétérinaire de Toulouse, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Hôpital Lariboisière, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)-CHU Rouen

Subjects
Oral, Infusions, Catheterization, Central Venous, Administration, Oral, MESH: Anticoagulants, Catheterization, MESH: Venous Thromboembolism, Kidney Failure, Central Venous, Neoplasms, Humans, MESH: Neoplasms, MESH: Heparin, Low-Molecular-Weight, Renal Insufficiency, MESH: Infusions, Intravenous, Infusions, Intravenous, MESH: Catheterization, Central Venous, MESH: Humans, Heparin, Low-Molecular-Weight, Anticoagulants, Venous Thromboembolism, Heparin, Low-Molecular-Weight, MESH: Kidney Failure, Administration, MESH: Administration, Oral, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Intravenous
Abstract

International audience; The Standards, Options: Recommendations (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events(VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française dEanesthésie-réanimation:SFAR).

Published
2008
Full Text
View/download PDF

6. [2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients]

Author

Debourdeau, Philippe, Farge-Bancel, Dominique, Bosquet, Lise, Kassab-Chahmi, Diana, Cajfinger, Francis, Desmurs-Clavel, Hélène, Desruennes, Eric, Douard, Marie-Cécile, Elias, Antoine, Elalamy, Ismail, Grange, Claire, Hocini, Hamid, Kriegel, Irène, Le Gal, Grégoire, Lévesque, Hervé, Mahé, Isabelle, Meyer, Guy, Mismetti, Patrick, Pavic, Michel, Quéré, Isabelle, Renaudin, Jean Marc, Scrobohaci, Marie-Lorraine, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de Médecine Interne, Hôpital Lariboisière, Ecole Vétérinaire de Toulouse, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université de Brest (UBO)-Université de Brest (UBO), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital Lariboisière-Fernand-Widal [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Oral, Male, Vena Cava Filters, MESH: Heparin, Hemorrhage, MESH: Anticoagulants, MESH: Catheterization, Catheterization, MESH: Venous Thromboembolism, Fibrinolytic Agents, Recurrence, Neoplasms, Thromboembolism, Humans, MESH: Fibrinolytic Agents, MESH: Neoplasms, MESH: Vena Cava Filters, Aged, MESH: Aged, MESH: Humans, MESH: Middle Aged, Heparin, Anticoagulants, Venous Thromboembolism, Middle Aged, MESH: Male, MESH: Recurrence, MESH: France, MESH: Thromboembolism, Administration, MESH: Administration, Oral, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Female, France, MESH: Female, MESH: Hemorrhage
Abstract

TheStandards, Options : Recommendations(SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events (VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies ("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française d'anesthésie-réanimation": SFAR).

Published
2008
Full Text
View/download PDF

7. [Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer]

Author

Kriegel, Irène, Desruennes, Eric, Douard, Marie-Cécile, Grange, Claire, Renaudin, Jean Marc, Meyer, Guy, Scrobohaci, Marie-Lorraine, Kassab-Chahmi, Diana, Bosquet, Lise, Cajfinger, Francis, Desmurs-Clavel, Hélène, Elias, Antoine, Elalamy, Ismail, Farge-Bancel, Dominique, Hocini, Hamid, Lévesque, Hervé, Mahé, Isabelle, Mismetti, Patrick, Pavic, Michel, Quéré, Isabelle, Le Gal, Grégoire, Debourdeau, Philippe, Centre de Recherche Roland Mousnier Histoire et Civilisation (CRM), École pratique des hautes études (EPHE)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Génomique, développement et pouvoir pathogène (GD2P), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA), Ecole Vétérinaire de Toulouse, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Signalisation cellulaire, dynamique circulatoire et athérosclérose précoce (SCDCAP), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Immunopathologie humaine, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Service de Médecine Interne, Hôpital Lariboisière, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris-Sorbonne (UP4)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Brest (UBO)-Université de Brest (UBO)

Subjects
Catheterization, Central Venous, MESH: Catheterization, Central Venous, MESH: Humans, Thrombosis, Catheterization, Central Venous, MESH: Thromboembolism, Neoplasms, Thromboembolism, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Humans, MESH: Neoplasms, MESH: Thrombosis, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2008

8. Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement

Author

Nevez, Gilles, Magois, Eline, Duwat, Hyacinthe, Jounieaux, Vincent, Totet, Anne, Coppo, Paul, Bengoufa, Djaouida, Veyradier, Agnès, Wolf, Martine, Bussel, Annette, Millot, Gael Armel, Malot, Sandrine, Heshmati, Farhad, Mira, Jean-Paul, Boulanger, Emmanuelle, Galicier, Lionel, Durey-Dragon, Marie-Agnès, Frémeaux-Bacchi, Véronique, Ramakers, Michel, Pruna, Anfré, Bordessoule, Dominique, Gouilleux, Valérie, Scrobohaci, Marie-Lorraine, Vernant, Jean-Paul, Moreau, Delphine, Azoulay, Elie, Schlemmer, Benoît, Guillevin, Loic, Lassoued, Kaiss, Pruna, André, Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Pneumology and Intensive Care, Departments of Medical Parasitology and Mycology, CHU Amiens-Picardie, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hématologie -Immunologie -Cibles thérapeutiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie, Hôpital Lariboisière, Hémostase et biologie vasculaire, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Dynamique de l'information génétique : bases fondamentales et cancer (DIGBFC), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie [AP-HP Hôpital Saint-Antoine], AP-HP - Hôpital Saint-Antoine, Unité de Médecine Transfusionnelle, CHU Cochin [AP-HP], Service de Réanimation Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Service d'Immunopathologie Clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'immunologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'immunologie biologique [Hôpital Européen Georges Pompidou [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de Soins Intensifs [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Laboratory of Immunology, Amiens University Hospital Centre, Unité de Greffe de Moelle Osseuse [CHU Henri Mondor], CHU Henri Mondor, L'Ecole des Hautes Etudes en Sciences Sociales (EHESS), École des hautes études en sciences sociales (EHESS)-School of Economics-Centre National de la Recherche Scientifique (CNRS), Medical ICU, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de réanimation médicale, Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Développement normal et pathologique des lymphocytes et signalisation, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Henri Mondor [Créteil], École des hautes études en sciences sociales (EHESS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, medicine.medical_specialty, Thrombotic microangiopathy, Anti-nuclear antibody, Adolescent, [SDV]Life Sciences [q-bio], ADAMTS13 Protein, 030204 cardiovascular system & hematology, Gastroenterology, Severity of Illness Index, Autoimmune Diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, von Willebrand Factor, medicine, Humans, Aged, Retrospective Studies, Autoimmune disease, Systemic lupus erythematosus, business.industry, Platelet Count, Metalloendopeptidases, Thrombosis, General Medicine, Middle Aged, medicine.disease, Prognosis, Thrombocytopenia, ADAMTS13, 3. Good health, Transplantation, ADAM Proteins, 030220 oncology & carcinogenesis, Immunology, Polyarthritis, Female, Kidney Diseases, medicine.symptom, business, Malar rash
Abstract

International audience; The significance of ADAMTS13 deficiency in adult thrombotic microangiopathy (TMA) remains controversial. In an attempt to define the characteristics of adult TMA with severe ADAMTS13 deficiency, we determined 2 groups of patients on the basis of ADAMTS13 activity (undetectable or detectable). Clinical presentation, laboratory values, autoimmune manifestations, and outcome were compared between the groups. Patients were included retrospectively from 12 centers. All fulfilled the diagnosis criteria of TMA. Patients with a history of transplantation, cancer and chemotherapy, and Centers for Disease Control and Prevention (CDC) stage C human immunodeficiency virus (HIV) infection were not included. Forty-six patients were included. Thirty-one patients had an undetectable ADAMTS13 activity (25%. Severe ADAMTS13 deficiency was associated with a plasmatic inhibitor in 17 cases (55%), suggesting an immune-mediated mechanism. Patients with undetectable ADAMTS13 were more frequently of Afro-Caribbean origin than patients with detectable ADAMTS13 activity (48.4% vs 13.3%, respectively; p = 0.03). As opposed to patients with detectable ADAMTS13 activity, patients with severe ADAMTS13 deficiency displayed various autoimmune manifestations that consisted of nondestructive polyarthritis (4 cases) associated in 1 case with malar rash and extramembranous glomerulonephritis, discoid lupus (3 cases), and autoimmune endocrinopathies, Raynaud phenomenon, and sarcoidosis-like disease (1 case each). In patients with severe ADAMTS13 deficiency, antinuclear antibodies, anti-double-stranded DNA antibodies, and anticardiolipin antibodies were positive in 22 (71%) cases, 3 (9.7%) cases, and 1 (3.2%) case, respectively. One patient fulfilled the criteria for the diagnosis of systemic lupus erythematosus. During follow-up, 1 patient with severe ADAMTS13 deficiency developed antinuclear antibodies, and 3 others developed anti-double-stranded DNA antibodies, in association with neurologic manifestations and anticardiolipin antibodies in 1 case. Patients with severe ADAMTS13 deficiency also had a lower platelet count (12 x 10(9)/L; range, 2-69 x 10(9)/L) and less severe renal failure (estimated glomerular filtration rate: 78 mL/min; range, 9-157 mL/min) than patients with detectable ADAMTS13 activity (49.5 x 10(9)/L; range, 6-103 x 10(9)/L; p = 0.0004, and 15.8 mL/min; range, 5.6-80 mL/min; p < 0.0001, respectively). End-stage renal failure occurred in 1 patient with severe ADAMTS13 deficiency and in 3 patients with detectable ADAMTS13 activity (3.2% vs 21.4%, respectively; p = 0.08). Flare-up and relapse episodes and survival were comparable between the groups. Taken together, these data indicate that adult idiopathic thrombotic thrombocytopenic purpura, as defined by severe ADAMTS13 deficiency, may occur preferentially in a particular ethnic group, and is characterized by severe thrombocytopenia, mild renal involvement, and a wide spectrum of autoimmune manifestations that may be completed during follow-up. Indeed, apparently idiopathic thrombotic thrombocytopenic purpura may be considered a specific autoimmune disease.

Published
2004
Full Text
View/download PDF

11. Platelet Aggregation and Populations in Acute Leukaemias

Author

Caen, J., Rendu, Francine, Sultan, Yvette, Gruyer, P., Scrobohaci, Marie-Lorraine, Levy-Toledano, Sylviane, Delobel, J., Flandrin, G., and Bernard, J.

Abstract

We have tried to correlate abnormal functions of platelets – mainly aggregation – with the cellular type of acute leukaemia. In acute lymphoblastic leukaemia, the abnormalities of platelet aggregation – when found – are related to plasmatic abnormalities. In acute monoblastic leukaemia, the platelet aggregation with ADP and the release are abnormal and the occurrence of a megacaryocytopathy is suggested. The results found in five cases of acute myeloblastic leukaemia – all peroxydase-positive – were heterogenous; three of the patients were abnormal, mainly with an abnormal release, while two – one of whom being pseudolymphoblastic – were normal when tested before or during effective therapy. These results can be helpful in the understanding of the marrow involvment in different types of acute leukaemia.

Published
1972
Full Text
View/download PDF

12. Platelet Aggregation and Populations in Acute Leukaemias

Author

Caen, J., primary, Rendu, Francine, additional, Sultan, Yvette, additional, Gruyer, P., additional, Scrobohaci, Marie-Lorraine, additional, Levy-Toledano, Sylviane, additional, Delobel, J., additional, Flandrin, G., additional, and Bernard, J., additional

Published
1972
Full Text
View/download PDF

13. Livedo Vasculitis With Protein C System Deficiency

Author

Baccard, Michel, Vignon-Pennamen, Marie Dominique, Janier, Michel, Scrobohaci, Marie Lorraine, and Dubertret, Louis

Abstract

TO THE EDITOR.— Protein C is a vitamin K—dependent plasma glycoprotein synthetized in the liver. Thrombomodulin (the endothelial receptor for thrombin) catalyzes the thrombin activation of protein C. Activated protein C has anticoagulant activity. Protein C deficiency is responsible for a hypercoagulable state that can be symptomatic.1Protein C deficiency is either acquired or is transmitted in an autosomal dominant fashion.1 Homozygous deficiency is responsible for neonatal purpura fulminans and disseminated intravascular coagulation within the first days of life. Heterozygous deficiency is responsible for deep-vein thrombosis in young adults. Development of skin necrosis in these patients during the initiation of oral anticoagulant therapy is also well known. It is probably caused by a rapid drop in protein C concentration, which has a shorter life than most of the procoagulant vitamin K—dependent factors, thus resulting in a transient hypercoagulable state.We report a case of livedo reticularis with superficial

Published
1992
Full Text
View/download PDF

14. [2008 Standards, Options: Recommendations for venous thromboembolic events(VTE)treatment and central venous catheter thrombosis(CVCT) management in cancer patients].

Author

Mahé I, Elalamy I, Farge-Bancel D, Mismetti P, Scrobohaci ML, Hocini H, Meyer G, Kassab-Chahmi D, Bosquet L, Cajfinger F, Desmurs-Clavel H, Desruennes E, Douard MC, Elias A, Grange C, Kriegel I, Le Gal G, Lévesque H, Pavic M, Renaudin JM, Quéré I, and Debourdeau P

Subjects
Administration, Oral, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Catheterization, Central Venous methods, Heparin, Low-Molecular-Weight administration & dosage, Heparin, Low-Molecular-Weight therapeutic use, Humans, Infusions, Intravenous, Renal Insufficiency complications, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Catheterization, Central Venous adverse effects, Neoplasms complications, Neoplasms therapy, Venous Thromboembolism therapy
Abstract

The Standards, Options: Recommendations (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events(VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française dEanesthésie-réanimation:SFAR).

Published
2008
Full Text
View/download PDF

15. [2008 Standards, Options: recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients].

Author

Debourdeau P, Farge-Bancel D, Bosquet L, Kassab-Chahmi D, Cajfinger F, Desmurs-Clavel H, Desruennes E, Douard MC, Elias A, Elalamy I, Grange C, Hocini H, Kriegel I, Le Gal G, Lévesque H, Mahé I, Meyer G, Mismetti P, Pavic M, Quéré I, Renaudin JM, and Scrobohaci ML

Subjects
Anticoagulants adverse effects, Anticoagulants therapeutic use, Catheterization adverse effects, Fibrinolytic Agents therapeutic use, France, Heparin adverse effects, Heparin therapeutic use, Humans, Vena Cava Filters, Venous Thromboembolism prevention & control, Neoplasms complications, Venous Thromboembolism therapy
Abstract

The <> (SOR) project has been undertaken by the French National Federation of Cancer Centers (FNCLCC) is now part of the French National Cancer Institute. The project involves the development and updating of evidence-based Clinical Practice Guidelines (CPG) in oncology. In order to answer questions related to venous thromboembolic events (VTE) treatment and to central venous catheter thrombosis (CVCT) management in cancer patients, the SOR elaborated national guidelines, here presented in a short report. It results of a collaborative work with members from three learned societies ("société nationale française de médicine interne": SNFMI, "société française de médicine vasculaire": SFMV and "société française d'anesthésie-réanimation": SFAR).

Published
2008
Full Text
View/download PDF

16. [Standards, Options: recommendations 2008; thromboembolic events treatment, prophylaxis and treatment of central venous catheter thrombosis in patients with cancer].

Author

Kriegel I, Desruennes E, Douard MC, Grange C, Renaudin JM, Meyer G, Scrobohaci ML, Kassab-Chahmi D, Bosquet L, Cajfinger F, Desmurs-Clavel H, Elias A, Elalamy I, Farge-Bancel D, Hocini H, Lévesque H, Mahé I, Mismetti P, Pavic M, Quéré I, Le Gal G, and Debourdeau P

Subjects
Catheterization, Central Venous adverse effects, Humans, Thromboembolism prevention & control, Thromboembolism therapy, Catheterization, Central Venous standards, Neoplasms complications, Thromboembolism etiology, Thrombosis etiology
Published
2008
Full Text
View/download PDF

17. [Pathophysiology of thrombotic microangiopathies: current understanding].

Author

Coppo P, Veyradier A, Durey MA, Fremeaux-Bacchi V, Scrobohaci ML, Amesland F, and Bussel A

Subjects
ADAM Proteins, ADAMTS13 Protein, Autoimmunity, Complement Factor H deficiency, Hemolytic-Uremic Syndrome etiology, Hemolytic-Uremic Syndrome pathology, Humans, Microcirculation, Platelet Aggregation, Purpura, Thrombotic Thrombocytopenic etiology, Purpura, Thrombotic Thrombocytopenic pathology, Risk Factors, Hemolytic-Uremic Syndrome physiopathology, Metalloendopeptidases deficiency, Purpura, Thrombotic Thrombocytopenic physiopathology, von Willebrand Factor physiology
Abstract

Thrombotic microangiopathies (TMA) encompass various severe diseases characterized by microangiopathic hemolytic anemia and peripheral thrombocytopenia, associated with fever, neurological signs and renal involvement. Microvascular thrombosis is the typical lesion, and results in tissue ischemia. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the two most classical forms. These two entities are clinically and histopathologically closely related. There is a body of evidence suggesting that endothelial cell injury is the initial event in TTP and HUS, and that it may be related to a large number of triggering factors, such as infection, connective tissue disease, drugs, cancer and chemotherapy, transplantation, and pregnancy. Endothelial cell injury enhances the release of ultra large forms of von Willebrand factor (ULvWF) multimers and other prothrombotic agents, such as plasminogen activator inhibitor and platelet activating factor, whereas it decreases the release of prostaglandin-I2, a strong inhibitor of platelet aggregation. Recently however, it has been shown that TTP and HUS were pathophysiologically distinct. Actually, TTP is associated with a deficiency in von Willebrand factor-cleaving protease, an enzyme involved in cleavage of ULvWF into circulating 200 kDa and 350 kDa fragments. This deficiency may be either congenital or acquired, and then related to an IgG inhibitory autoantibody. This protease deficiency may account for the high amounts of plasmatic ULvWF in TTP patients. In HUS, vWF-cleaving protease activity is found normal. HUS encompasses two distinct entities. Epidemic, or diarrhea-associated HUS, is associated with verotoxin or Shiga toxin-associated enterobacteriaceae. These toxins are directly responsible for endothelial cell injury. Sporadic HUS (also termed atypical HUS in children) is closely related to TTP, and shares the same triggering factors. Familial HUS has been associated in some cases with hypocomplementemia and factor H dysfunction, the pathophysiological role of which remains unclear. The study of the different triggering factors and predisposing factors may be useful to define different subsets of TMA, that may be characterized by their course and prognosis.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results